Livanova Plc (LIVN) Stock Price & Analysis
Livanova Plc (LIVN) rose 3.17% to USD 77.17 as of June 10, 2026 at 01:00 UTC, according to Nexqual real-time market data.
LIVN last closed at USD 74.8; the session ranged USD 75.95–77.78 on volume of 658,613 shares. Market capitalization is $4.24B, with a 52-week range of USD 41.02–77.78 (NMS). Source: Nexqual, June 10, 2026 at 01:00 UTC.
Key Statistics (as of June 10, 2026 at 01:00 UTC)
| Price | USD 77.17 |
|---|---|
| Change | ▲ 3.17% (up) |
| Previous Close | USD 74.8 |
| Open | USD 76.92 |
| Day Range | USD 75.95 – 77.78 |
| 52-Week Range | USD 41.02 – 77.78 |
| Volume | 658,613 shares |
| Market Cap | $4.24B |
| Exchange | NMS |
Technical Analysis (LIVN)
Nexqual's technical model rates LIVN "BUY" based on 5 bullish and 2 bearish signals across 124 daily candles, as of June 10, 2026 at 01:00 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 63.74 (neutral) |
| vs SMA50 | Above (USD 67.76) |
| MACD | 2.01 (positive) |
Analyst Ratings (LIVN)
Wall Street analysts rate LIVN "Buy" based on 10 analysts, with a mean price target of USD 80.6 (range USD 67–95), per Nexqual as of June 10, 2026 at 01:00 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 10 |
| Mean Target | USD 80.6 |
| High Target | USD 95 |
| Low Target | USD 67 |
| Buy / Hold / Sell | 8 / 2 / 0 |
Earnings (LIVN)
| Next Earnings Date | 2026-08-05 |
|---|---|
| EPS Estimate | USD 1.09 |
| Revenue Estimate | $380.57M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.98 vs est 0.9 ▲ beat |
| 2025-12-31 | USD 0.86 vs est 0.81 ▲ beat |
| 2025-09-30 | USD 1.11 vs est 0.92 ▲ beat |
| 2025-06-30 | USD 1.05 vs est 0.87 ▲ beat |
Source: Nexqual, June 10, 2026 at 01:00 UTC.
Financials & Fundamentals (LIVN)
| Total Revenue | $1.43B |
|---|---|
| Revenue Growth (YoY) | +14.30% |
| Gross Margin | +67.86% |
| Operating Margin | +14.39% |
| Profit Margin | +7.47% |
| ROE | +9.54% |
| Debt / Equity | 28.35 |
| Current Ratio | 1.33 |
| Total Cash | $539.71M |
| Total Debt | $343.44M |
| Free Cash Flow | $198.05M |
Source: Nexqual, June 10, 2026 at 01:00 UTC.
Financial Health Score (LIVN)
Nexqual rates Livanova Plc's overall financial health "Solid" across five dimensions, as of June 10, 2026 at 01:00 UTC.
| Growth | Solid — Revenue +11% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 68%, operating 14% |
| Balance Sheet | Strong — $540M cash vs $343M debt, net cash position |
| Cash Flow | Solid — FCF $198M, 14% margin |
| Efficiency | Mixed — ROE 10%, ROA 5.3% |
Ownership (LIVN)
| Insider Ownership | +0.36% |
|---|---|
| Institutional Ownership | +112.31% |
| Shares Outstanding | 54.93M |
| Float | 54.69M |
| Short % of Float | +6.99% |
Source: Nexqual, June 10, 2026 at 01:00 UTC.
Leadership (LIVN)
Livanova Plc is led by Vladimir A. Makatsaria (age 52), CEO & Director, per Nexqual as of June 10, 2026 at 01:00 UTC.
| CEO & Director | Vladimir A. Makatsaria (age 52) |
|---|---|
| Chief Financial Officer | Alex Shvartsburg C.M.A. (age 55) |
| Vice President of Investor Relations | Briana Gotlin |
| Vice President of Corporate Communications | Deanna Wilke |
| Chief Strategy & Corporate Development Officer | Philip Kowalczyk |
Major Backers & Investors (LIVN)
Notable institutional backers of Livanova Plc include Primecap Management Company, Artisan Partners Limited Partnership, American Century Companies Inc, according to Nexqual as of June 10, 2026 at 01:00 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Primecap Management Company | 7.66% |
| Artisan Partners Limited Partnership | 6.26% |
| American Century Companies Inc | 6.22% |
| FMR, LLC | 4.85% |
| AQR Capital Management, LLC | 4.54% |
| Millennium Management | 4.44% |
| Wellington Management | 3.44% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 18.68% |
| State Street | 3.77% |
| Vanguard Group | 3.48% |
Source: Nexqual, June 10, 2026 at 01:00 UTC.
From Livanova Plc's Latest SEC 10-K Filing (filed 2026-02-25)
Key Strengths & Strategy (as disclosed to the SEC)
- LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services in the United States, the United Kingdom, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, Denmark, and internationally.
- The company operates in two segments, Cardiopulmonary and Neuromodulation.
- The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannulae, and other related accessories, as well as services related products.
- The Neuromodulation segment offers VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals; and devices that deliver neuromodulation therapy for treating drug-resistant epilepsy and difficult-to-treat depression.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ITGR | Integer Holdings Corporation | USD 94.1 | ▲ 2.3% |
| CNMD | CONMED Corporation | USD 36.9 | ▲ 4.95% |
| SGRY | Surgery Partners, Inc. | USD 13.96 | ▲ 1.82% |
| ICUI | ICU Medical, Inc. | USD 142 | ▲ 3.95% |
| VREX | Varex Imaging Corporation | USD 10.62 | ▲ 5.25% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 01:00 UTC. This page is informational and not investment advice.